Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,733,660 shares of the life sciences company's stock after purchasing an additional 5,833 shares during the period. Geode Capital Management LLC owned 1.72% of Illumina worth $364,670,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. HighPoint Advisor Group LLC increased its holdings in shares of Illumina by 15.9% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,121 shares of the life sciences company's stock worth $283,000 after purchasing an additional 291 shares in the last quarter. Cannell & Spears LLC lifted its position in Illumina by 3.9% during the fourth quarter. Cannell & Spears LLC now owns 664,473 shares of the life sciences company's stock valued at $88,794,000 after purchasing an additional 24,716 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Illumina by 84.2% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 6,374 shares of the life sciences company's stock valued at $852,000 after acquiring an additional 2,913 shares during the period. CIBC Private Wealth Group LLC raised its stake in Illumina by 1.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 165,305 shares of the life sciences company's stock valued at $23,090,000 after purchasing an additional 1,801 shares during the period. Finally, Schroder Investment Management Group grew its stake in Illumina by 32.5% during the fourth quarter. Schroder Investment Management Group now owns 196,860 shares of the life sciences company's stock valued at $26,295,000 after acquiring an additional 48,263 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Illumina Price Performance

Shares of Illumina stock traded down $6.43 on Thursday, reaching $69.87. The company's stock had a trading volume of 790,938 shares, compared to its average volume of 2,571,888. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a market capitalization of $11.07 billion, a P/E ratio of -9.12, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $90.77 and a 200-day moving average price of $123.08.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Robert W. Baird dropped their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Piper Sandler raised their target price on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Guggenheim lowered their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Illumina has a consensus rating of "Moderate Buy" and an average price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.